national coverage determination

After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest.

The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.

While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.

The company hopes to simultaneously achieve premarket FDA approval and a national coverage determination from CMS for its NGS cancer panel.

The firm has billed commercial insurers for more than 17,000 tests and reported test results for more than 15,000 Medicare patients without receiving payment.

OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.